Skip to content

The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome

The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome: Double-blind, Randomized, Placebo-controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01637714
Enrollment
70
Registered
2012-07-11
Start date
2012-07-31
Completion date
2013-07-31
Last updated
2013-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diarrhea Predominant Irritable Bowel Syndrome

Brief summary

The investigators will evaluate the efficacy of multi-strain probiotics in adults with diarrhea predominant irritable bowel syndrome.

Interventions

* B. longum BORI: 1 x 109 * B. bifidum BGN4: 1 x 109 * B. lactis AD011: 1 x 109 * B. infantis IBS007: 1 x 109 * Lactobacillus acidophilus AD031: 1 x 109 three times a day, within 10 minutes after meal, per oral with water

DRUGPlacebo powder

same taste, shape, dosage as experimental drug three times a day, within 10 minutes after meal, per oral with water

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* willing to consent/undergo necessary procedures * between the age of 19 and 75 years * diarrhea predominant irritable bowel syndrome (satisfied with Rome II criteria)

Exclusion criteria

* uncontrolled hypertension (Blood pressure \> 180/110 mmHg) * uncontrolled diabetes mellitus (FBS \> 200 mg/dL) * malignancy, cerebrovascular disease, cardiovascular disease * history of abdominal surgery except appendectomy and hernia repair * inflammatory bowel disease * clinically or laboratory-confirmed gastroenteritis * the use of motility drug or dietary fiber supplement in 2 weeks * serum Cr \> 2 x Upper normal limit * AST or ALT \> 2 x Upper normal limit * Pregnancy, Lactating woman

Design outcomes

Primary

MeasureTime frameDescription
change of Irritable bowel syndrome symptom severity score (IBS-SSS)after 8 weeksSeverity and frequency of abdominal pain / abdominal bloating / bowel habitus / interfere degree of daily life

Secondary

MeasureTime frameDescription
Assessment for patient satisfaction after administration completionafter 4 weeks and 8 weeks
Stool frequency and formafter 4 weeks and 8 weeksStool frequency (greater than 3 bowel movements/day or less than 3 bowel movements/week) Stool form (lumpy / hard or loose / watery stool)
Symptom control of irritable bowel syndromeafter 4 weeks and 8 weeks
Improvement of overall symptom in patient with irritable bowel syndromeafter 4 weeks and 8 weeks
Assessment for quality of life related with irritable bowel syndromeafter 4 weeks and 8 weeks

Countries

South Korea

Contacts

Primary ContactJoo Sung Kim, M.D., PhD
jooskim@snu.ac.kr+82-2-740-8112
Backup ContactKyoung Sup Hong, M.D.
kshong1@empas.com+82-10-2578-5738

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026